LRFN4 Inhibitors
LRFN4 Inhibitors are a class of chemical compounds that indirectly reduce the functional activity of leucine-rich repeat and fibronectin type III domain containing 4 (LRFN4) by targeting various signaling pathways and molecules that regulate the cellular processes in which LRFN4 is involved. Bisindolylmaleimide I, by inhibiting Protein kinase C, impedes the activation of downstream proteins that would normally interact with or regulate LRFN4, potentiallyleading to decreased synaptic organization and function. Y-27632 disrupts Rho-associated protein kinase, which is critical for actin cytoskeleton organization-a process LRFN4 is implicated in-thereby indirectly affecting its role in synaptic organization. PD98059 and SB203580 target the MAPK/ERK and p38 MAPK pathways, respectively, which are linked to cellular responses that involve LRFN4. The inhibition of these kinases by these compounds could lead to a reduction in LRFN4 activity due to diminished downstream signaling.
Additionally, PI3K inhibitors like LY294002 and Wortmannin can lead to decreased activation of downstream molecules such as Akt, which can affect the function of LRFN4 in neuronal signaling and synaptic plasticity. U73122's inhibition of phospholipase C can hinder pathways that involve calcium signaling and protein kinase C, potentially reducing LRFN4 activity. NF449's targeting of the Gs-alpha subunit of G-protein coupled receptors may also decrease LRFN4 activity by interrupting G-protein-mediated signaling. BAPTA-AM functions as a calcium chelator, which by buffering intracellular calcium levels, can modulate LRFN4's role in calcium-dependent signaling pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Protein kinase C (PKC) inhibitor that specifically binds to the regulatory domain of PKC, preventing its activation. LRFN4 modulates synapse formation through PKC-dependent signaling pathways. Inhibition of PKC can reduce the phosphorylation and activity of proteins downstream, including LRFN4. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Selective inhibitor of ROCK (Rho-associated protein kinase), which is implicated in actin cytoskeleton organization. LRFN4 is involved in cell adhesion and dendritic spine development, processes that are dependent on the actin cytoskeleton dynamics. By disrupting ROCK activity, Y-27632 can indirectly affect LRFN4's role in synaptic organization. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor that blocks the MAPK/ERK pathway. LRFN4's synaptic functions are modulated by extracellular signals that converge on the MAPK/ERK pathway. By inhibiting MEK, PD98059 impairs the downstream signaling that would normally influence the activity of LRFN4. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor that impedes cellular responses to stress and inflammatory cytokines. LRFN4 is indirectly modulated by stress-activated protein kinase pathways, including p38 MAPK. SB203580 can decrease the functional activity of LRFN4 by inhibiting these pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor that blocks the PI3K/Akt pathway, important for many cellular processes including neuronal signaling. Inhibition of PI3K can result in reduced phosphorylation and activation of downstream molecules that may affect the synaptic functions of LRFN4. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor similar to LY294002, Wortmannin binds irreversibly to PI3K and hinders its phosphorylation activity. This can lead to reduced synaptic signaling and potential downregulation of LRFN4 activity, given its role in synapse formation. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $203.00 $469.00 $1509.00 | 1 | |
Potent and selective inhibitor of Gs-alpha subunit of G-protein. Given that LRFN4 has been implicated in G-protein-coupled receptor signaling, NF449 can inhibit the functional activity of LRFN4 by disrupting Gs-alpha-mediated signaling pathways. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
Calcium chelator that can buffer intracellular calcium levels. Since LRFN4 is involved in calcium-dependent cellular processes, such as neuronal signaling, BAPTA-AM can indirectly inhibit LRFN4 function by altering intracellular calcium dynamics. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
Inhibitor of myosin light chain kinase (MLCK), which is crucial for myosin-mediated contraction in cells. LRFN4, being associated with cell adhesion, could be influenced by changes in cytoskeletal dynamics controlled by MLCK. ML-7 may thus reduce LRFN4-mediated signaling. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
Specific inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII). CaMKII is involved in the regulation of neurotransmitter release and synaptic plasticity. Since LRFN4 is part of the mechanisms that organize synapses, KN-93 may indirectly inhibit LRFN4 function by altering CaMKII activity. | ||||||